Chennai Journal

DelveInsight Business Research LLP

DelveInsight’s ‘Liver Fibrosis-Market Insights, Epidemiology, and Market Forecast–2032’ report deliver an in-depth understanding of the Liver Fibrosis, historical and forecasted epidemiology as well as the Liver Fibrosis market trends in the United States, EU4(Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Liver Fibrosis Market Overview

Fibrosis, also known as fibrotic scarring, is a pathological wound healing in which connective tissue replaces normal parenchymal tissue to the extent that it goes unchecked, leading to considerable tissue remodeling and the formation of permanent scar tissue.

Repeated injuries, chronic inflammation, and repair are susceptible to fibrosis, where an accidental excessive accumulation of extracellular matrix components, such as collagen, is produced by fibroblasts, leading to the formation of a permanent fibrotic scar.[1]

In response to injury, this is called scarring, and if fibrosis arises from a single cell line, this is called a fibroma. Physiologically, fibrosis acts to deposit connective tissue, which can interfere with or totally inhibit the normal architecture and function of the underlying organ or tissue. Fibrosis can be used to describe the pathological state of excess deposition of fibrous tissue, as well as the process of connective tissue deposition in healing. Defined by the pathological accumulation of extracellular matrix (ECM) proteins, fibrosis results in scarring and thickening of the affected tissue . It is, in essence, an exaggerated wound-healing response that interferes with normal organ function.

Learn more about the Liver Fibrosis market @ Liver Fibrosis Market Landscape

 Liver Fibrosis Epidemiological Segmentation 

• Liver Fibrosis incident cases

• Liver Fibrosis treated cases

• Liver Fibrosis diagnosed cases

• Liver Fibrosis prevalent cases 

Liver Fibrosis Market Outlook 

Liver fibrosis is the result of excessive accumulation of the extracellular matrix of the liver due to chronic liver injury, and fibrosis is considered as a model for the wound healing response. This process is associated with an inflammatory response in which extracellular matrix (ECM) deposition is restricted. Persistent liver damage causes liver regeneration to fail, and hepatocytes are replaced by large amounts of ECM, including collagen. There is growing optimism that new medications that favor the natural history of the disease are likely to emerge within the next 3-5 years. Due to the lack of standard treatment, liver transplantation is the only treatment option available for severe and advanced fibrosis cases. The FDA has approved no drug for fibrosis and NASH, but few studies have shown promising results. According to the guidelines of the American Liver Foundation, Vitamin E is commonly prescribed to patients with NAFLD / NASH and works by reducing or neutralizing the damage caused by inflammation. However, vitamin E as an antioxidant and pioglitazone as an insulin sensitizer have shown some efficacy against NASH in randomized controlled trials (RCTs). In upcoming drug scenarios, there are a plethora of companies investigating agents for use in NASH based Fibrosis which are Inventiva Pharma, Galmed Pharmaceuticals, Madrigal Pharma, Galectin Therapeutics, Intercept Pharmaceuticals, Galectin Therapeutics Inc., Zydus Therapeutic. There are many more pharma companies that are conducting clinical trials for therapies of liver fibrosis or NASH.

Key Companies in the Liver Fibrosis Market Include

• Inventiva Pharma

• Galmed Research and Development, Ltd.

• Madrigal Pharmaceuticals, Inc.

• Intercept Pharmaceuticals

• Galectin Therapeutics Inc.

• Zydus Therapeutics

• Axcella Therapeutics,

And many others 

Liver Fibrosis Therapies Covered and Analyzed in the Report Market Include:

• Lanifibranor

• Aramchol

• FG-3019

• Entecavir

• Oltipraz

• BMS-986036

 Learn more about the Liver Fibrosis Market, Key Companies, and Emerging Therapies 

Table of Contents

1. Key Insights 

2. Liver Fibrosis  Report Introduction 

3. Executive Summary of the Liver Fibrosis  Market  

4. Liver Fibrosis  Disease Background and Overview

5. Liver Fibrosis  Epidemiology and patient population

6. Liver Fibrosis  Market Emerging Therapies

7. Liver Fibrosis  Market Drivers 

8. Liver Fibrosis  Market Barriers 

9. Market Access and Reimbursement of Therapies

10. Appendix

11. Report Methodology

12. DelveInsight Capabilities

13. Disclaimer

14. About DelveInsight

Learn more about the detailed report offerings @ Liver Fibrosis Market Outlook

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services